Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
Status:
Completed
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity
of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary
nonbullous or bullous impetigo.